Hydrus Microstent
Alcon Research, LLC · Decision date Apr 23, 2026
What did the FDA decide?
FDA records P170034/S017 as a supplement to PMA P170034, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 23, 2026.
FDA approval order statement
an addition of alternate suppliers for non-patient contacting components of the device delivery system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170034/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Research, LLC
- Product code
- OGO
- Decision code
- OK30
- Decision date
- Apr 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intraocular pressure lowering implant.
- Applicant
- Alcon Research, LLC
- Product code
- OGO
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170034/S017 received
Application receipt date recorded by FDA.
P170034/S017 · FDA decision
30-Day Notice
P170034/S018 · Related supplement
Hydrus Microstent
Timeline entries are records held by MedtechLedger for P170034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Hydrus MicrostentP170034/S018 | Alcon Research, LLC | PMA supplement | Jun 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OGO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Glaukos Corporation | PMA supplement | Oct 1, 2026 | FDA | |
iStent Trabecular Micro-Bypass Stent SystemP080030/S027 | Glaukos Corporation | PMA supplement | Apr 8, 2026 | FDA |
| Glaukos Corporation | PMA approval | Jun 21, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Research, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P170034/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

